Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.

David D StenehjemAndrew W HahnDavid M GillDaniel AlbertsonBanumathy GowrishankarJoseph MerrimanArchana M AgarwalVenkata ThodimaErik B HarringtonTrang H AuBenjamin L MaughanJane HouldsworthSumanta K PalNeeraj Agarwal

Published in: PloS one (2019)

In mRCC, a composite model of TP53 mutation, wild type VHL, and FLT1 C/C variant strongly predicted PFS on first-line VEGF TT in a dose-dependent manner. These findings require external validation.

Keyphrases

wild type
metastatic renal cell carcinoma
vascular endothelial growth factor
endothelial cells
acute myeloid leukemia
tyrosine kinase
copy number